Takeda Pharmaceutical (TAK) Competitors $15.03 -0.08 (-0.53%) Closing price 03:59 PM EasternExtended Trading$14.96 -0.07 (-0.50%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TAK vs. SNY, GSK, ARGX, BNTX, ONC, SMMT, TEVA, ITCI, GMAB, and RDYShould you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Takeda Pharmaceutical vs. Sanofi GSK argenx BioNTech Beigene Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking. Which has higher earnings and valuation, SNY or TAK? Sanofi has higher earnings, but lower revenue than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.29B2.98$6.02B$2.8018.69Takeda Pharmaceutical$4.58T0.01$994.06M$0.4037.58 Does the MarketBeat Community prefer SNY or TAK? Takeda Pharmaceutical received 50 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.71% of users gave Sanofi an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformSanofiOutperform Votes5160.71% Underperform Votes3339.29% Takeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Which has more risk & volatility, SNY or TAK? Sanofi has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Is SNY or TAK more profitable? Sanofi has a net margin of 12.77% compared to Takeda Pharmaceutical's net margin of 4.53%. Sanofi's return on equity of 25.61% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi12.77% 25.61% 14.72% Takeda Pharmaceutical 4.53%9.39%4.53% Is SNY or TAK a better dividend stock? Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.5%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Do institutionals & insiders have more ownership in SNY or TAK? 14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to SNY or TAK? In the previous week, Sanofi had 23 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 30 mentions for Sanofi and 7 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 1.15 beat Takeda Pharmaceutical's score of 0.84 indicating that Sanofi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 18 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate SNY or TAK? Sanofi presently has a consensus target price of $63.33, suggesting a potential upside of 21.05%. Given Sanofi's higher possible upside, equities analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySanofi beats Takeda Pharmaceutical on 16 of the 20 factors compared between the two stocks. Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAK vs. The Competition Export to ExcelMetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$47.82B$6.68B$5.44B$18.91BDividend Yield3.49%3.20%5.44%4.14%P/E Ratio37.587.1422.1432.57Price / Sales0.01238.91389.7128.52Price / Cash4.2765.6738.2017.53Price / Book0.986.266.664.45Net Income$994.06M$142.48M$3.21B$1.02B7 Day Performance2.35%7.91%5.83%3.51%1 Month Performance-0.13%-6.03%-4.31%-5.38%1 Year Performance15.04%-0.96%17.83%4.23% Takeda Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAKTakeda Pharmaceutical2.3385 of 5 stars$15.03-0.5%N/A+14.4%$47.82B$4.58T37.5847,300SNYSanofi3.8442 of 5 stars$50.93+0.1%$63.33+24.4%+14.9%$128.66B$44.29B20.4591,600Earnings ReportNews CoverageGSKGSK1.7673 of 5 stars$36.52+1.6%$40.58+11.1%-8.3%$75.35B$31.38B22.9790,100Upcoming EarningsAnalyst UpgradeAnalyst RevisionARGXargenx3.4819 of 5 stars$595.70-0.1%$699.28+17.4%+60.1%$36.20B$2.19B-676.93650News CoveragePositive NewsBNTXBioNTech2.4903 of 5 stars$101.81+3.1%$143.44+40.9%+36.8%$24.43B$2.75B-48.483,080Analyst RevisionONCBeigene3.1627 of 5 stars$229.22-0.8%$316.71+38.2%N/A$22.66B$3.81B-27.829,000Analyst ForecastNews CoverageSMMTSummit Therapeutics2.6308 of 5 stars$25.22+2.5%$35.40+40.4%+922.3%$18.15B$700,000.00-90.07110Upcoming EarningsAnalyst ForecastNews CoverageGap DownTrading HaltedTEVATeva Pharmaceutical Industries3.0933 of 5 stars$13.30-2.6%$23.43+76.2%+13.1%$15.08B$16.54B-9.1736,800Analyst UpgradePositive NewsITCIIntra-Cellular Therapies2.2135 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.2305 of 5 stars$20.07+0.1%$39.17+95.2%-27.9%$13.28B$21.53B11.531,660Analyst RevisionRDYDr. Reddy's Laboratories2.4993 of 5 stars$13.68+0.1%$17.00+24.3%-1.3%$11.42B$311.31B21.7824,800Positive News Related Companies and Tools Related Companies SNY Competitors GSK Competitors ARGX Competitors BNTX Competitors ONC Competitors SMMT Competitors TEVA Competitors ITCI Competitors GMAB Competitors RDY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TAK) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TAK Stock Free TAK Stock Alerts